Investing.com - Mesoblast reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Mesoblast announced earnings per share of $-0.19 on revenue of $2.1M. Analysts polled by Investing.com anticipated EPS of $-0.145 on revenue of $3.16M.
Mesoblast shares are down 23.33% from the beginning of the year and are trading at $3.680 , down-from-52-week-high.They are under-performing the Nasdaq which is down 17.73% from the start of the year.
Mesoblast follows other major Healthcare sector earnings this month
Mesoblast's report follows an earnings beat by UnitedHealth on Thursday, April 14, 2022, who reported EPS of $5.49 on revenue of $80.15B, compared to forecasts EPS of $5.36 on revenue of $78.73B.
J&J had beat expectations on Tuesday, April 19, 2022 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar